Uniphar Plc

Uniphar Plc, based in Ireland, provides vital pharmaceutical services and medical device distribution, enhancing healthcare access across Europe. Their comprehensive solutions support healthcare providers, pharmacies, and medical institutions in delivering timely and efficient services. Uniphar Plc is a healthcare service provider that specializes in pharmaceutical services and medical device distribution. Founded in 1967 and headquartered in Dublin, Ireland, the company has engaged in 3 notable deals.

In March 2025, Allianz Global Investors participated in a PIPE investment round, acquiring a minority stake for EUR 149,268. 72, which helped raise a total of EUR 0. 149 mn. Uniphar Group provides comprehensive solutions in the healthcare sector, primarily focusing on medical device distribution and pharmaceutical services.

Its core product offerings include a wide range of medical devices and high-value services aimed at enhancing access to medicines across their product life cycle. The company serves a diverse client base that includes healthcare providers, pharmacies, and medical institutions across multiple European markets, such as the UK, Germany, and France. Uniphar's services are designed to address critical healthcare challenges, ensuring that end users, including patients and healthcare professionals, have timely access to essential medical products. This focused approach not only streamlines supply chains but also optimizes the distribution process, thus reinforcing Uniphar's position in Ireland.

Uniphar Group has reported revenues amounting to EUR 2. 80 bn for the fiscal year ending in 2024. The company's revenue model typically involves B2B transactions, where it acts as a distributor for pharmacomedical manufacturers and directly serves healthcare facilities and pharmacies. Partnerships with over 200 pharmacomedical manufacturers enable Uniphar to offer a variety of medical devices and pharmaceutical products, thus facilitating a robust supply chain.

Though specific pricing plans for individual products and services are proprietary, the transaction structure generally includes wholesale agreements where healthcare entities purchase medical devices in bulk at negotiated rates. This systematic approach to revenue generation underscores Uniphar's commitment to delivering value within the healthcare ecosystem. In March 2025, Uniphar plans to leverage the recent PIPE investment to further enhance its product offerings and expand its market reach. The company is developing new medical devices aimed at addressing emerging healthcare needs, with a targeted launch date in the second half of 2025.

Additionally, Uniphar intends to enter new European markets to broaden its service network and improve access to its pharmaceutical solutions. The recent funding will be key in supporting these initiatives.